piperazine has been researched along with pyrimidine in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (85.71) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Fotsch, C; St Jean, DJ | 1 |
Hao, M; Li, G; Li, Y; Wang, Y; Yan, Y; Yang, L; Zhang, S | 1 |
Dai, H; Doran, SD; Piotrowski, DW; Prakash, C; Ryder, TF; Sharma, R; Sun, H | 1 |
Baranowski, TC; Barnes, S; Blake, AL; Bojarski, AJ; Ehalt, AJ; Fernando, NT; Klenc, J; Paranjpe, S; Raszkiewicz, A; Raux, EA; Sączewski, J; Satała, G; Strekowski, L; Sullivan, SM | 1 |
Ahmed, N; Hassan, MI; Idrees, D; Khan, P; Parveen, I | 1 |
Bajda, M; Bednarski, M; Bucki, A; Czopek, A; Głuch-Lutwin, M; Jastrzębska-Więsek, M; Jończyk, J; Koczurkiewicz, P; Kołaczkowski, M; Partyka, A; Pawłowski, M; Piska, K; Siwek, A; Wesołowska, A; Zagórska, A | 1 |
Chalapathi, PV; Nagalakshmamma, V; Nagaraju, C; Pasala, C; Thyagaraju, K; Umamaheswari, A; Venkataswamy, M | 1 |
1 review(s) available for piperazine and pyrimidine
Article | Year |
---|---|
Mitigating heterocycle metabolism in drug discovery.
Topics: Animals; Biotransformation; Databases, Factual; Drug Discovery; Drug Interactions; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Pharmaceutical Preparations; Rats | 2012 |
6 other study(ies) available for piperazine and pyrimidine
Article | Year |
---|---|
Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Topics: Biological Availability; Glutamic Acid; Heterocyclic Compounds, 1-Ring; Humans; Molecular Dynamics Simulation; Piperazine; Piperazines; Platelet Aggregation; Protein Conformation; Purinergic P2Y Receptor Antagonists; Pyridines; Pyrimidines; Quantitative Structure-Activity Relationship; Receptors, Purinergic P2Y12; Reproducibility of Results | 2011 |
Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
Topics: Amides; Animals; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Dogs; Feces; Female; Humans; Hydrolysis; Hydroxylation; Male; Metabolic Detoxication, Phase II; Microsomes, Liver; Molecular Docking Simulation; Piperazine; Piperazines; Pyrimidines; Pyrrolidines; Rats; Rats, Sprague-Dawley | 2012 |
Synthesis and Structure-Activity Relationship Analysis of 5-HT₇ Receptor Antagonists: Piperazin-1-yl Substituted Unfused Heterobiaryls.
Topics: Humans; Ligands; Piperazine; Piperazines; Pyrimidines; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship | 2016 |
Synthesis, estrogen receptor binding affinity and molecular docking of pyrimidine-piperazine-chromene and -quinoline conjugates.
Topics: Antineoplastic Agents; Benzopyrans; Binding Sites; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Piperazine; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Quinolines; Structure-Activity Relationship | 2017 |
Characteristics of metabolic stability and the cell permeability of 2-pyrimidinyl-piperazinyl-alkyl derivatives of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione with antidepressant- and anxiolytic-like activities.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Binding Sites; Imidazoles; Maze Learning; Mice; Microsomes, Liver; Molecular Dynamics Simulation; Permeability; Phosphoric Diester Hydrolases; Piperazine; Protein Binding; Protein Structure, Tertiary; Purines; Pyrimidines; Receptor, Serotonin, 5-HT1A; Structure-Activity Relationship | 2019 |
Design, synthesis, anti-tobacco mosaic viral and molecule docking simulations of urea/thiourea derivatives of 2-(piperazine-1-yl)-pyrimidine and 1-(4-Fluoro/4-Chloro phenyl)-piperazine and 1-(4-Chloro phenyl)-piperazine - A study.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Piperazine; Pyrimidines; Structure-Activity Relationship; Tobacco Mosaic Virus; Urea | 2020 |